Vol. 18/No. 22 | OncologyLive

Immunotherapy Resistance Remains a Puzzle

December 15, 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Most Patients in Need of HCT Can Now Get Transplants

December 11, 2017

Due to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.